Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Electrocardiographic and Echocardiographic predictors of paroxysmal atrial fibrillation detected after ischemic stroke

  • Maria A. Baturova1, 2Email author,
  • Seth H. Sheldon3,
  • Jonas Carlson1,
  • Peter A. Brady3,
  • Grace Lin3,
  • Alejandro A. Rabinstein4,
  • Paul A. Friedman3 and
  • Pyotr G. Platonov1, 5
BMC Cardiovascular DisordersBMC series – open, inclusive and trusted201616:209

https://doi.org/10.1186/s12872-016-0384-2

Received: 19 April 2016

Accepted: 25 October 2016

Published: 3 November 2016

Abstract

Background

Detection of atrial fibrillation after ischemic stroke is challenging due to its paroxysmal nature. We aimed to assess predictors of paroxysmal atrial fibrillation using non-invasive surface ECG and transthoracic echocardiography to select candidates for atrial fibrillation screening.

Methods

Ischemic stroke patients without documented atrial fibrillation (n = 110, 67 ± 10 years, 40 female) and a control group of age- and gender-matched patients with history of paroxysmal atrial fibrillation prior to stroke (n = 55, 67 ± 10 years, 19 female) comprised the study sample. Using non-invasive ECG monitoring for three weeks, short episodes of paroxysmal atrial fibrillation were detected in 24 of 110 patients (22 %). The standard 12-lead ECG with sinus rhythm at stroke onset was digitally processed and analyzed. Transthoracic echocardiography data were reviewed for these patients.

Results

Atrial fibrillation history was independently associated with P terminal force in lead V 1 > 40 mm*ms (OR 4.04 95 % CI 1.34–12.14, p = 0.013) and left atrial volume index (OR 1.08 95 % CI 1.03–1.13, p = 0.002; for LAVI > 40 mL/m2 OR 6.40 95 % CL 1.47–27.91, p = 0.013). Among patients without atrial fibrillation history, no ECG characteristics were predictive of atrial fibrillation detected after stroke. Left atrial volume index remained an independent predictor of atrial fibrillation detected after stroke (OR 1.09 95 % CI 1.02–1.16, p = 0.017). A cutoff of <40 mL/m2 had an 84 % negative predictive value for ruling out atrial fibrillation on ambulatory monitoring with a sensitivity of 50 % and a specificity of 86 %.

Conclusion

In a post hoc analysis, left atrial dilatation assessed by left atrial volume index independently predicted atrial fibrillation after stroke in patients without prior atrial fibrillation history, while the other clinical or ECG markers were not predictive of atrial fibrillation detected early after ischemic stroke.

Trial registration

This study is a post hoc analysis from the prospective case-control study registered in December 2011, ClinicalTrials.gov ID: NCT01325545.

Keywords

Atrial fibrillation Ischemic stroke ECG Left atrial volume index

Background

The high prevalence of atrial fibrillation (AF) in ischemic stroke patients is well-documented [1, 2]. Detecting AF after ischemic stroke is important, as anticoagulation therapy, as opposed to aspirin, is hence used to prevent recurrent thromboembolic events. However, paroxysmal AF is often underdiagnosed. Routine diagnostic screening techniques, such as 24-h Holter ECG monitoring, have modest sensitivity for AF detection [3, 4]. Prolonged electrocardiographic (ECG) monitoring increases the detection rate of AF after a stroke [5]. However, the highest detection rate of AF after cryptogenic stroke was reported in stroke patients with implantable cardiac monitors (ICM) [6]. While ICM-based strategy for AF detection is clearly superior to other ECG monitoring techniques, its cost effectiveness is largely affected by proper patient selection, which highlights the need for developing AF risk prediction tools.

Atrial remodeling in patients with known AF can be demonstrated using available non-invasive techniques, such as surface ECG and transthoracic echocardiography (TTE). It is not fully clear whether the same ECG and TTE measures are associated with newly-detected AF after ischemic stroke and may be used to select candidates for more costly and time consuming AF screening.

Frequent supraventricular ectopic activity, including frequent supraventricular premature complexes and supraventricular runs detected by 24-h Holter ECG monitoring, are predictive of AF [7, 8]. A case-control study using ambulatory ECG monitoring for three weeks after a stroke showed that short episodes of asymptomatic AF are common in both patients with cryptogenic stroke and patients with stroke of known cause [9]. Identifying clinical markers predictive of AF after stroke would facilitate AF screening in patients at high risk for developing arrhythmia, and help optimize the use of health care resources.

We aimed to investigate clinical, ECG and TTE characteristics associated with paroxysmal AF in ischemic stroke patients, and to assess whether the same clinical, ECG and TTE parameters are predictive of paroxysmal AF detected using ambulatory ECG monitoring early after ischemic stroke.

Methods

Study cohort

The study cohort was recruited from the cohort of ischemic stroke patients treated at Mayo Clinic (Rochester, MN, USA). Patients without history of AF or atrial flutter prior to or at the index stroke event were compared with patients with documented paroxysmal AF by admission with stroke.

Study group of patients without AF history comprised of 110 patients with ischemic stroke of either cryptogenic (n = 55) or known cause (n = 55) who were previously included in the recently published analysis [9] and who had a surface ECG during sinus rhythm obtained at stroke onset (mean age 67 ± 10 years, 40 female). Using ambulatory ECG monitoring for three weeks (Mobile Cardiac Outpatient Telemetry system - CardioNet, Conshohocken, PA, USA), short AF episodes of median 6 s duration (IQR 6–9) were detected in 24 patients (22 %). All arrhythmic episodes were manually reviewed by a board certified electrophysiologist. The 24 patients with newly detected short AF episodes after stroke (ShortAF Group) were compared to the 86 stroke patients without detected AF (NoAF Group).

Control group was randomly selected from age- and gender-matched patients treated at Mayo Clinic with ischemic stroke with history of paroxysmal AF prior to stroke and sinus rhythm on standard 12-lead ECG at admission (PxAF Group, n = 55, 67 ± 10 years, 19 female).

The Mayo Clinic Institutional Review Board approved the research protocol.

Baseline assessment

Baseline clinical assessment included demographics, body mass index (BMI), comorbid conditions such as cardiac failure, hypertension, ischemic heart diseases, stroke or transient ischemic attack in the past, diabetes and cardiovascular risk profile measured by CHADS2 and CHA2DS2-VASc scales [10].

ECG analysis

Standard clinical 12-lead ECG recordings with sinus rhythm were obtained at enrollment in all study subjects. Digital signals were extracted and stored in a format readable by MegaCare ECG management system (Siemens-Elema, Stockholm, Sweden. Discontinued). Standard clinical measurements, i.e., P-wave duration, QRS duration, corrected QT interval (using Bazett’s formula), PQ interval and P-wave terminal force in Lead V1 were obtained from the MegaCare system using the University of Glasgow 12-lead ECG analysis algorithm [11]. P-wave terminal force in Lead V1 was defined as duration, in milliseconds, of the terminal (negative) part of the P wave multiplied by its depth in millimeters [12].

P-wave morphology assessment was performed using custom-made software running on MATLAB R2013b (The MathWorks, Inc., Natick, MA, USA) for Linux. The 12-lead ECG was mathematically transformed into orthogonal leads using the pseudo-inverse of the Dower transformation matrix [13]. The orthogonal leads were denoted X (right-left), Y (up-down), and Z (front-back).

In addition to conventional P-wave indices, we analyzed gross morphology of P-waves using an automatic algorithm [14] that classified orthogonal P waves into types as having positive polarity in leads X and Y and negative, biphasic (-/+) or positive polarity in lead Z. Biphasic (+/-) P-waves in inferior lead Y have been defined as an advanced interatrial block with retrograde left atrial activation (IAB).

Echocardiography

Results of clinically indicated TTE were retrieved from patient medical records. TTE examinations were performed at median 1 day (interquartile range 25–75 % (IQR) -10.9 to 2.9 months) from the stroke event. We assessed the left atrial volume index (LAVI, ml/m2), ejection fraction (EF), estimated right atrial pressure using inferior vena cava size and respiratory variation (mm Hg), right ventricular pressure (mm Hg), left ventricular end-systolic and end-diastolic internal dimensions (mm).

Statistical methods

Clinical characteristics, ECG and TTE parameters were compared between patients in the NoAF Group and patients in the ShortAF Group using chi-square or Fisher’s exact test for categorical variables and Student’s t-test for continuous variables with an approximate normal distribution or alternatively non-parametric tests, as appropriate.

To identify predictors of paroxysmal AF on prolonged ambulatory ECG monitoring, significantly associated covariates were further evaluated in univariate logistic regression models with estimation of odds ratios and likelihood-ratio tests. Factors significantly associated with occurrence of short AF episodes on ECG monitoring in the univariate models were subsequently included in a stepwise multivariate regression analysis with backwards elimination. Predictive accuracy of covariates determined in multivariate logistic regression models was evaluated using receiver operating characteristic (ROC) curve analysis with calculation of positive predictive value, negative predictive value, sensitivity and specificity of the determined parameters.

The group of patients without history of AF prior to or at the index stroke event was compared to patients in the PxAF Group. Univariate logistic regression analysis was performed to identify covariates significantly associated with AF history that were further included in a stepwise multivariate regression analysis with backwards elimination. Threshold values for F-to-enter and F-to-remove were 0.05 and 0.1, respectively.

All analyses were performed using SPSS Statistics 20 (SPSS Inc., Chicago, Illinois, USA). P-values of <0.05 were considered significant.

Results

Clinical characteristics associated with history of paroxysmal AF in ischemic stroke patients

PxAF patients had a higher proportion of vascular diseases, cardiac failure and higher cardiovascular risk profile measured by CHADS2 and CHA2DS2-VASc scales than patients without AF at baseline (Table 1).
Table 1

Clinical, ECG and Echocardiographic characteristics of stroke patients without AF history at stroke onset and patients with history of AF prior to stroke

Variables

Patients without AF history, n = 110

Patients with PxAF, n = 55

P value

Mean age, yearsa

67 ± 10

68 ± 10

0.686

Female, n (%)

40 (36)

19 (35)

0.864

BMIa

29 ± 5

29 ± 5

0.790

P-wave duration, msa

137 ± 16

145 ± 17

0.003

Patients with P-wave duration > 120 ms, n (%)

90 (82)

47 (85)

0.387

PR-interval, msa

172 ± 28

178 ± 35

0.189

P-wave terminal force in lead V1, mm x msa

24 ± 26

35 ± 33

0.020

QRS duration, msa

100 ± 17

107 ± 21

0.021

Corrected QTc interval, msa

430 ± 28

454 ± 34

<0.001

P-wave morphology

  

0.435

X(+)Y(+)Z(-), n (%)

19 (19)

8 (16)

 

X(+)Y(+)Z(-/+), n (%)

60 (59)

32 (64)

 

IAB or X(+)Y(+/-), n (%)

2 (2)

3 (6)

 

X(+)Y(+)Z(+), n (%)

21 (21)

7 (14)

 

Left atrium volume index, ml/m2

35 ± 12

45 ± 12

<0.001

EF, %a

58 ± 12

52 ± 15

0.027

Left ventricular end-systolic internal demension, mma

33 ± 9

37 ± 10

0.033

Left ventricular end-diastolic internal demension, mma

49 ± 7

52 ± 8

0.049

Right atrium pressure, mmHga

6 ± 2

8 ± 5

0.007

Right ventricular systolic pressure, mmHga

34 ± 10

36 ± 12

0.242

Diabetes, n (%)

18 (16)

12 (22)

0.399

Hypertension, n (%)

84 (76)

41 (75)

0.848

Vascular diseases, n (%)

21 (19)

20 (36)

0.021

Cardiac failure, n (%)

6 (6)

16 (29)

<0.001

CHADS2 scorea

3.2 ± 0.9

3.5 ± 1.0

0.034

CHA2DS2-VASc scorea

4.9 ± 1.5

4.9 ± 1.5

0.028

a - the results are cited as mean value ± standard deviation

Analysis of ECG data showed that P-wave duration, QRS duration, corrected QT interval were longer, and P-wave terminal force in lead V1 was greater in PxAF patients than in patients without AF at stroke. The distribution of different P-wave morphologies was similar in both groups. P-wave morphology with positive P-waves in leads X, Y and biphasic P-wave in lead Z was the most prevalent type in our study cohort.

TTE examination revealed that patients with AF history had lower EF, higher right atrium systolic pressure, larger left ventricular end-systolic and end-diastolic internal dimensions and greater LAVI than patients without AF.

However, in multivariate logistic regression analysis, only vascular diseases (odds ratio (OR) 4.10 95 % CI 1.32–12.78, p = 0.015), P-wave terminal force in lead V1 greater 40 mm*ms (OR 4.04 95 % CI 1.34–12.14, p = 0.013) and LAVI (OR 1.08 95 % CI 1.03–1.13, p = 0.002) remained significantly associated with AF prior to stroke.

Predictors of short AF episodes detected after ischemic stroke in patients without AF history

Clinical, ECG and TTE data are summarized in the Table 2.
Table 2

Clinical, ECG and Echocardiographic characteristics of stroke patients without AF history at stroke event

 

NoAF Group, n = 86

ShortAF Group, n = 24

P value

Mean age, yearsa

66 ± 10

71 ± 9

0.033

Men, n (%)

55 (64)

15 (63)

1.000

BMIa

31 ± 23

30 ± 6

0.761

P-wave duration, msa

136 ± 15

143 ± 18

0.232

Patients with P-wave duration > 120 ms, n (%)

70 (81)

20 (83)

0.451

PR-interval, msa

175 ± 29

158 ± 22

0.007

P-wave terminal force in lead V1, mm x msa

23 ± 24

28 ± 35

0.394

QRS duration, msa

100 ± 18

100 ± 15

0.962

QTc, msa

430 ± 28

430 ± 28

1.000

PW morphology

  

0.570

X(+)Y(+)Z(-), n (%)

16 (20)

3 (14)

 

X(+)Y(+)Z(-/+), n (%)

45 (56)

15 (71)

 

IAB or X(+)Y(+/-), n (%)

2 (3)

0 (0)

 

X(+)Y(+)Z(+), n (%)

18 (22)

3 (14)

 

Left atrium volume index, ml/m2

32 ± 10

42 ± 15

0.007

EF, %

58 ± 12

56 ± 13

0.499

Left ventricular S, mma

33 ± 9

35 ± 8

0.496

Left ventricular D, mma

49 ± 7

50 ± 6

0.679

Right atrial pressure, mmHga

6 ± 2

6 ± 2

0.498

Right ventricular systolic pressure, mmHga

33 ± 11

36 ± 7

0.490

Diabetes, n (%)

17 (20)

1 (4)

0.115

Hypertension, n (%)

66 (76)

18 (75)

1.000

Ischemic heart disease, n (%)

17 (20)

4 (17)

1.000

Cardiac failure, n (%)

4 (5)

2 (9)

0.604

CHADS2 scorea

3.2 ± 0.9

3.2 ± 0.9

0.996

CHA2DS2-VASc scorea

4.3 ± 1.5

4.5 ± 1.4

0.579

a- the results are cited as mean value ± standard deviation

Patients with AF detected on ECG monitoring were older than patients without detected AF, with no differences in sex, BMI, cardiovascular comorbidities or cardiovascular risk profile measured by CHADS2 and CHA2DS2-VASc scales. These patients had greater LAVI than patients without AF, and there were no differences in other ECG (including P-wave morphology) and TTE characteristics.

In univariate regression analysis, detection of short AF episodes after stroke was associated only with age and LAVI. However, LAVI remained the only independent predictor of AF in multivariate regression analysis (Table 3).
Table 3

Covariates associated with short AF episodes on ambulatory ECG monitoring detected in patients without prior AF history

 

Univariate regression model

Multivariate regression model (adjusted for age)

Variables

OR

95 % CI

P value

OR

95 % CI

P value

aLAVI

1.08

1.01–1.15

0.017

1.08

1.01–1.15

0.017

aLAVI > 40 ml/m2

6.40

1.47–27.91

0.013

6.40

1.47–27.91

0.013

P-wave duration

1.03

1.00–1.06

0.082

   

QRS duration

1.00

1.00–1.03

0.961

   

Corrected QT interval

1.00

1.00–1.02

0.988

   

PTF

1.00

1.00–1.00

0.393

   

EF

1.00

1.00–1.03

0.493

   

Left ventricle end-diatolic dimension

1.02

1.00–1.12

0.672

   

Left ventrical end-systolic dimension

1.03

1.00–1.10

0.488

   

Right atrium pressure

1.11

0.82–1.52

0.492

   

Age

1.05

1.00–1.11

0.037

   

Hypertension

0.91

0.32–2.60

0.859

   

Ischemic heart diseases

0.81

0.25–2.69

0.733

   

Cardiac failure

1.86

0.35–10.85

0.488

   

a- multivariate analysis was performed separately for LAVI as continuous variable and for LAVI > 40 ml/m2

The area under the ROC curve values for LAVI as an indicator of the short AF episodes detected by ambulatory ECG monitoring was 0.698, p = 0.041 (Fig. 1). A cutoff of <40 mL/m2 had a positive predictive value of 55 % and an 84 % negative predictive value for ruling out AF on ambulatory monitoring, with sensitivity 50 % and specificity 86 %.
Fig. 1

ROC curve for LAVI to detect short episodes of AF on ambulatory ECG monitoring

Discussion

Detecting AF after ischemic stroke is challenging due to its paroxysmal nature. Studies with implantable devices have shown that most AF episodes are asymptomatic [15, 16], and thus AF often remains undetected. Routine ECG monitoring strategies have moderate sensitivity in AF detection, and there is therefore a need to find a simple non-invasive tool to identify stroke survivors who would benefit more from continuous screening for AF.

Our main finding is that left atrial dilatation measured by LAVI is the strongest independent predictor of subsequent detection of short AF episodes during prolonged ECG monitoring in patients without AF at stroke onset. ECG data, including P-wave morphology, and underlying comorbidities have limited value for predicting paroxysmal AF after ischemic stroke. In patients with known paroxysmal AF, however, a negative terminal deflection in V1 was a strong indicator of arrhythmia.

The novelty of our finding is that the presence of electrocardiographic abnormalities in patients with known AF, but not in those without history of AF, suggests that initially there is development of subtle structural changes seen by TTE (increased LAVI), and electrocardiographic abnormalities are only seen later.

Short episodes of paroxysmal AF

In patients without AF history at stroke onset, we found very short episodes of paroxysmal AF during 3 weeks of ECG monitoring. It is still under discussion whether ultra-short AF episodes of less than 30 s have the same risk of thromboembolic complications as manifested AF [17]. However, it has been shown that supraventricular runs and high supraventricular ectopic activity are predictive of AF occurrence [7, 8]. In ischemic stroke patients, premature atrial complexes that occur more frequently than 4 per hour and atrial runs that exceed 5 complexes were associated with occurrence of paroxysmal AF [18]. Studies with loop recorders implanted for AF screening after ischemic stroke reported detection of AF lasting 2 min or longer on average 48–68 days after implantation [19, 20]. While short episodes of paroxysmal AF were common for our ischemic stroke cohort who underwent ambulatory ECG monitoring for 3 weeks, the monitoring time was perhaps not long enough to reveal full incidence of underlying asymptomatic AF in this stroke cohort. Short episodes of paroxysmal AF may be considered as “surrogates” for prolonged AF that should be used for identifying stroke patients who would benefit from continuous screening for AF.

It is uncertain whether short episodes of AF indicate the need for anticoagulation therapy. The TRENDS study in patients with implantable devices showed that AF burden exceeding 5.5 h during any of the preceding 30 days appeared to double the thromboembolic risk [15]. However, in the ASSERT study in patients with implantable devices it has been shown that most patients who had stroke while being monitored did not have AF at the time and 30 days prior to the stroke onset [16].

As reported recently, early anticoagulation therapy for incident AF and withdrawal of anticoagulation therapy after arrhythmia-free periods do not improve outcomes in patients with implantable devices as compared with conventional management [21]. Additional studies are needed to investigate the benefit of anticoagulant therapy in patients with short asymptomatic episodes of paroxysmal AF.

Atrial remodeling predisposing to atrial fibrillation

Left atrial volume index

Left atrial dilatation measured as increase in LAVI may be a marker of underlying structural changes in the atrium leading to the development of AF in patients without advanced cardiovascular disorders. Notably, it has been shown that LAVI was associated with first-ever ischemic stroke in patients without previous AF. [22] One possible explanation for this association is that blood stasis and thrombus formation may occur more often in a left atrium of increased size even when AF is not present [23]. Another possible explanation is that these patients actually have undetected paroxysmal AF that was not present at the time of stroke. Furthermore, inflammation and structural changes due to underlying comorbidity may be more important than atrial fibrillation in the development of atrial myopathy. The CHA2DS2VASC score increases stroke risk even in the absence of known AF [24].

Increased LAVI reflects remodeling of left atrium due to pressure or volume overload [25] and correlates with the extent of left atrial fibrosis [26]. Both atrial remodeling and atrial fibrosis are pathological changes associated with the development of AF.

It has been shown that LAVI has a high diagnostic accuracy for AF in hypertensive patients with historical paroxysmal AF [27]. This was confirmed in our study for stroke patients with known AF. We have also shown that even in patients without history of AF, LAVI independently predicted AF detected by ambulatory ECG monitoring early after ischemic stroke, and can be used in routine clinical practice as a valuable index for selecting patients for continuous ECG monitoring for AF detection. LAVI < 40 mL/m2 has a high negative predictive value for ruling out short AF episodes on ambulatory ECG monitoring. This approach may decrease the number of patients undergoing ambulatory ECG monitoring after stroke and consequently reduce costs of medical care for this patient population. Conversely, patients with LAVI > 40 mL/m2 are more likely to have episodes of asymptomatic AF and should be screened for AF more thoroughly.

In our study, LAVI was associated with history of AF independently from other TTE characteristics, and was higher in patients with history of AF than in patients with short AF episodes. While the difference was not significant (perhaps due to the small number of patients with detected AF after stroke), we observed a trend of gradual LAVI increase from its lowest value in patients without any AF, to intermediate volume in patients with short AF episodes, and highest LAVI in patients with a history of AF. This trend may reflect the underlying progression structural changes in the left atrium in patients who develop AF.

ECG data

In order to assess ECG predictors of AF detected shortly after ischemic stroke, we used ECG characteristics that were reported to be associated with AF in earlier studies.

One of the most studied markers of atrial conduction is P-wave duration. P-wave prolongation reflects atrial remodeling predisposing to occurrence of AF. In the Framingham Heart Study, the prolongation of P-wave duration predicted the development of AF during long-term follow-up in an elderly community-based cohort [28]. In hypertensive patients, prolonged P-wave duration was associated with AF incidence during 25 ± 3 months [29]. In our study, the majority of patients initially had prolonged P-wave duration, but no association was found between P-wave duration and AF on ambulatory ECG monitoring. These findings are in line with an earlier report of absent association between P-wave prolongation and incident AF among patients with advanced congestive heart failure and prolonged P-waves at baseline in the MADIT-II study [14].

Sinus P-waves with biphasic morphology in the sagittal plane (right precordial leads or orthogonal lead Z) quantified as increase of negative terminal force in lead V1 (e.g. P terminal force in lead V1) was predominantly found in the elderly [30] and in patients with a history of AF [31] or structural heart disease [32]. The Atherosclerosis Risk in Communities study found that P terminal force in lead V1 greater than 4000 μV * ms was associated with an increased risk of AF. [33] In our study, P terminal force in lead V1 greater than 40 mm*ms was independently associated with history of AF, which is in line with previously reported data.

In summary, while ECG characteristics in patients with established AF and documented arrhythmia prior to stroke expectedly had prolonged P-waves and more prominent P terminal force in lead V1, none of these ECG characteristics was independently predictive of paroxysmal AF detected in the cohort of patients without prior AF history. While patients with short AF episodes had longer P-wave duration and greater P terminal force in lead V1, the difference did not reach statistical significance. The apparent lack of association between AF detection after stroke and P-wave abnormalities is perhaps due to the fact that most patients included in our study had underlying cardiovascular comorbidities and atrial fibrosis affecting P-wave duration and morphology. Another explanation for this is that P-wave abnormalities are a later finding in atrial myopathy disease progression than LAVI enlargement, and our patients were relatively early in their disease progression.

It is possible that we did not have enough patients with short AF episodes detected after stroke in our study, thus possibly undermining our ability to identify an association with P-wave duration and morphology. However, LAVI as a marker of structural left atrial remodeling was significantly associated with history of AF and had strong predictive value for incident AF, thus demonstrating its superiority over ECG indices. Indeed, future studies could determine whether increased LAVI alone may predict which patients would fulfill the indications for initiating oral anticoagulation therapy.

Study limitations

The main limitation of our study is the relatively small number of patients who had short AF episodes on ambulatory ECG monitoring; this small patient population may affect the interpretation of negative findings of the lack of predictive value of ECG indices for incident AF. Our analysis is also affected by limitations inherent in the study’s retrospective design. We used cinically indicated TTE data obtained from patients’ medical records. While most patients had TTE done at the time of admission with ischemic stroke (median time 1 day after stroke), we can not completely rule out the impact of TTE timing in relation to stroke on its predictive value with regard to new-onset AF during follow-up.

Consequently, our findings should be considered hypothesis-generating and need to be independently reproduced in further studies.

Conclusion

LAVI is the strongest independent predictor of paroxysmal AF detected after ischemic stroke. LAVI may be considered as an early marker of asymptomatic AF in stroke patients without history of AF and advanced structural changes in the heart, which may help identify patients who would benefit from intensive monitoring for AF detection. Most stroke patients with LAVI < 40 mL/m2 are less likely to develop paroxysmal AF on prolonged ambulatory ECG monitoring.

Abbreviations

AF: 

Atrial fibrillation

BMI: 

Body mass index

ECG: 

Electrocardiographic

EF: 

Ejection fraction

IQR: 

Interquartile range 25–75 %

LAVI: 

Left atrial volume index

OR: 

Odds ratio

Px: 

Paroxysmal

ROC: 

Receiver operating characteristic

TTE: 

Transthoracic echocardiography

Declarations

Acknowledgements

None.

Funding

This post hoc analysis is based on data collected in a study supported by an unrestricted grant from CardioNet (Conshohocken, PA, USA), which had no input or relationship with the present analysis. Dr. Baturova was supported by the Swedish Institute, Dr. Platonov was supported by the Swedish Heart-Lung Foundation and the Swedish National Health Service, Skåne University Hospital, Lund, Sweden.

Availability of data and materials

The data supporting the results and conclusions of the survey might be available from the corresponding author on reasonable request.

Authors’ contributions

MB made substantial contributions to data conception, design, analysis and interpretation; she wrote the manuscript; was responsible for portions of the content and all aspects of ensuring that any questions related to accuracy or integrity are appropriately investigated and resolved. SS was responsible for the data collection, analysis and interpretation; he was involved in drafting the manuscript. JC was responsible for the data, analysis and interpretation; he was involved in drafting the manuscript. PB made substantial contributions to conception, design, analysis and interpretation of data; was responsible for manuscript revision. GL was responsible for the data collection and manuscript revision. AR made substantial contributions to conception, design, and data acquisition, analysis and interpretation; he was involved in drafting the manuscript. PF made substantial contributions to conception, design and data acquisition, analysis and interpretation; he was involved in drafting the manuscript; agreed to be accountable for all aspects of work in ensuring that any questions related to accuracy or integrity are appropriately investigated and resolved. PP made substantial contributions to conception, design, data acquisition, analysis and interpretation; he was involved in drafting and revising the manuscript; agreed to be accountable for all aspects of work in ensuring that any questions related to accuracy or integrity are appropriately investigated and resolved. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This study is a post hoc analysis from the prospective case-control study conducted at Mayo Clinic (ClinicalTrials.gov ID: NCT01325545). The Mayo Clinic Institutional Review Board approved the research protocol of the case-control study and the informed consent. All participants signed informed consent in order to take part in the study according to research protocol.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Cardiology, Clinical Science, Lund University
(2)
University Clinic, St. Petersburg State University
(3)
Department of Cardiology, Mayo Clinic
(4)
Department of Neurology, Mayo Clinic
(5)
Arrhythmia Clinic, Skåne University Hospital

References

  1. Henriksson KM, Farahmand B, Asberg S, Terent A, Edvardsson N. First-ever atrial fibrillation documented after hemorrhagic or ischemic stroke: the role of the CHADS(2) score at the time of stroke. Clin Cardiol. 2011;34(5):309–16.View ArticlePubMedGoogle Scholar
  2. Baturova MA, Lindgren A, Shubik YV, Olsson SB, Platonov PG. Documentation of atrial fibrillation prior to first-ever ischemic stroke. Acta Neurol Scand. 2014;129(6):412–9.View ArticlePubMedGoogle Scholar
  3. Schaer BA, Zellweger MJ, Cron TA, Kaiser CA, Osswald S. Value of routine holter monitoring for the detection of paroxysmal atrial fibrillation in patients with cerebral ischemic events. Stroke. 2004;35(3):e68–70.View ArticlePubMedGoogle Scholar
  4. Suissa L, Lachaud S, Mahagne MH. Optimal Timing and Duration of Continuous Electrocardiographic Monitoring for Detecting Atrial Fibrillation in Stroke Patients. J Stroke Cerebrovasc Dis. 2013;22(7):991-5.Google Scholar
  5. Rabinstein AA. Prolonged cardiac monitoring for detection of paroxysmal atrial fibrillation after cerebral ischemia. Stroke. 2014;45(4):1208–14.View ArticlePubMedGoogle Scholar
  6. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, Rymer MM, Thijs V, Rogers T, Beckers F, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370(26):2478–86.View ArticlePubMedGoogle Scholar
  7. Wallmann D, Tuller D, Wustmann K, Meier P, Isenegger J, Arnold M, Mattle HP, Delacretaz E. Frequent atrial premature beats predict paroxysmal atrial fibrillation in stroke patients: an opportunity for a new diagnostic strategy. Stroke. 2007;38(8):2292–4.View ArticlePubMedGoogle Scholar
  8. Binici Z, Intzilakis T, Nielsen OW, Kober L, Sajadieh A. Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. Circulation. 2010;121(17):1904–11.View ArticlePubMedGoogle Scholar
  9. Rabinstein AA, Fugate JE, Mandrekar J, Burns JD, Seet RC, Dupont SA, Kauffman TJ, Asirvatham SJ, Friedman PA. Paroxysmal atrial fibrillation in cryptogenic stroke: a case-control study. J Stroke Cerebrovasc Dis. 2013;22(8):1405–11.View ArticlePubMedGoogle Scholar
  10. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–429.View ArticlePubMedGoogle Scholar
  11. Macfarlane PW, Devine B, Clark E. The University of Glasgow (Uni-G) ECG analysis program. Computers in Cardiology. 2005;32:451–4.Google Scholar
  12. Kohsaka S, Sciacca RR, Sugioka K, Sacco RL, Homma S, Di Tullio MR. Electrocardiographic left atrial abnormalities and risk of ischemic stroke. Stroke. 2005;36(11):2481–3.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Edenbrandt L, Pahlm O. Vectorcardiogram synthesized from a 12-lead ECG: superiority of the inverse Dower matrix. J Electrocardiol. 1988;21(4):361–7.View ArticlePubMedGoogle Scholar
  14. Holmqvist F, Platonov PG, McNitt S, Polonsky S, Carlson J, Zareba W, Moss AJ. Abnormal P-wave morphology is a predictor of atrial fibrillation development and cardiac death in MADIT II patients. Ann Noninvasive Electrocardiol. 2010;15(1):63–72.View ArticlePubMedGoogle Scholar
  15. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C, Qi D, Ziegler PD. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol. 2009;2(5):474–80.View ArticlePubMedGoogle Scholar
  16. Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, Lau CP, Van Gelder IC, Hohnloser SH, Carlson M, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014;129(21):2094–9.View ArticlePubMedGoogle Scholar
  17. Seet RC, Friedman PA, Rabinstein AA. Prolonged rhythm monitoring for the detection of occult paroxysmal atrial fibrillation in ischemic stroke of unknown cause. Circulation. 2011;124(4):477–86.View ArticlePubMedGoogle Scholar
  18. Weber-Kruger M, Groschel K, Mende M, Seegers J, Lahno R, Haase B, Niehaus CF, Edelmann F, Hasenfuss G, Wachter R, et al. Excessive supraventricular ectopic activity is indicative of paroxysmal atrial fibrillation in patients with cerebral ischemia. PLoS One. 2013;8(6). e67602.Google Scholar
  19. Cotter PE, Martin PJ, Ring L, Warburton EA, Belham M, Pugh PJ. Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke. Neurology. 2013;80(17):1546–50.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Ritter MA, Kochhauser S, Duning T, Reinke F, Pott C, Dechering DG, Eckardt L, Ringelstein EB. Occult atrial fibrillation in cryptogenic stroke: detection by 7-day electrocardiogram versus implantable cardiac monitors. Stroke. 2013;44(5):1449–52.View ArticlePubMedGoogle Scholar
  21. Martin DT, Bersohn MM, Waldo AL, Wathen MS, Choucair WK, Lip GY, Ip J, Holcomb R, Akar JG, Halperin JL. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. Eur Heart J. 2015;36(26):1660–8.View ArticlePubMedGoogle Scholar
  22. Barnes ME, Miyasaka Y, Seward JB, Gersh BJ, Rosales AG, Bailey KR, Petty GW, Wiebers DO, Tsang TS. Left atrial volume in the prediction of first ischemic stroke in an elderly cohort without atrial fibrillation. Mayo Clin Proc. 2004;79(8):1008–14.View ArticlePubMedGoogle Scholar
  23. Di Tullio MR, Sacco RL, Sciacca RR, Homma S. Left atrial size and the risk of ischemic stroke in an ethnically mixed population. Stroke. 1999;30(10):2019–24.View ArticlePubMedGoogle Scholar
  24. Glotzer TV, Hellkamp AS, Lee KL, Lamas GA. CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation. Can J Cardiol. 2015;31(8):1004–11.View ArticlePubMedGoogle Scholar
  25. Abhayaratna WP, Seward JB, Appleton CP, Douglas PS, Oh JK, Tajik AJ, Tsang TS. Left atrial size: physiologic determinants and clinical applications. J Am Coll Cardiol. 2006;47(12):2357–63.View ArticlePubMedGoogle Scholar
  26. Yalcin MU, Gurses KM, Kocyigit D, Canpinar H, Canpolat U, Evranos B, Yorgun H, Sahiner ML, Kaya EB, Hazirolan T, et al. The Association of Serum Galectin-3 Levels with Atrial Electrical and Structural Remodeling. J Cardiovasc Electrophysiol. 2015;26(6):635-40.Google Scholar
  27. Toh N, Kanzaki H, Nakatani S, Ohara T, Kim J, Kusano KF, Hashimura K, Ohe T, Ito H, Kitakaze M. Left atrial volume combined with atrial pump function identifies hypertensive patients with a history of paroxysmal atrial fibrillation. Hypertension. 2010;55(5):1150–6.View ArticlePubMedGoogle Scholar
  28. Magnani JW, Johnson VM, Sullivan LM, Gorodeski EZ, Schnabel RB, Lubitz SA, Levy D, Ellinor PT, Benjamin EJ. P wave duration and risk of longitudinal atrial fibrillation in persons >/= 60 years old (from the Framingham Heart Study). Am J Cardiol. 2011;107(6):917–921.e911.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Ciaroni S, Cuenoud L, Bloch A. Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension. Am Heart J. 2000;139(5):814–9.View ArticlePubMedGoogle Scholar
  30. Havmoller R, Carlson J, Holmqvist F, Herreros A, Meurling CJ, Olsson B, Platonov P. Age-related changes in P wave morphology in healthy subjects. BMC Cardiovasc Disord. 2007;7:22.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Platonov PG, Carlson J, Ingemansson MP, Roijer A, Hansson A, Chireikin LV, Olsson SB. Detection of inter-atrial conduction defects with unfiltered signal-averaged P-wave ECG in patients with lone atrial fibrillation. Europace. 2000;2(1):32–41.View ArticlePubMedGoogle Scholar
  32. Holmqvist F, Platonov PG, Carlson J, Havmoller R, Waktare JE, McKenna WJ, Olsson SB, Meurling CJ. Variable interatrial conduction illustrated in a hypertrophic cardiomyopathy population. Ann Noninvasive Electrocardiol. 2007;12(3):227–36.View ArticlePubMedGoogle Scholar
  33. Magnani JW, Zhu L, Lopez F, Pencina MJ, Agarwal SK, Soliman EZ, Benjamin EJ, Alonso A. P-wave indices and atrial fibrillation: cross-cohort assessments from the Framingham Heart Study (FHS) and Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2015;169(1):53–61.e51.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2016